CEBPA methylation and mutation in myelodysplastic syndrome

DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia

(2014) Jiang Lin et al.   LEUKEMIA RESEARCH

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases

(2013) Annette Fasan et al.   PLoS One

Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome

(2012) Qin Chen et al.   BRITISH JOURNAL OF HAEMATOLOGY

C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia

(2012) Meritxell Alberich-Jordà et al.   JOURNAL OF CLINICAL INVESTIGATION

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis

(2012) O Quintana-Bustamante et al.   LEUKEMIA

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia

(2012) V Grossmann et al.   Blood Cancer Journal

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome

(2011) Jiang Lin et al.   ANNALS OF HEMATOLOGY

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

(2011) Elizabeth A. Griffiths et al.   Epigenetics

The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure

(2011) Hui Jiang et al.   LEUKEMIA RESEARCH

Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

(2011) Jiang Lin et al.   PLoS One

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

(2010) E. Taskesen et al.   BLOOD

The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated

(2010) B. A. Santana-Lemos et al.   HAEMATOLOGICA

Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia

(2010) I. H. I. M. Hollink et al.   HAEMATOLOGICA

CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia

(2010) T-C Lin et al.   LEUKEMIA

Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features

(2010) Philippe Szankasi et al.   LEUKEMIA RESEARCH

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

(2009) T Pabst et al.   BRITISH JOURNAL OF CANCER

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells

(2008) Peggy Kirstetter et al.   CANCER CELL

Epigenetic Modification of CCAAT/Enhancer Binding Protein   Expression in Acute Myeloid Leukemia

(2008) B. Hackanson et al.   CANCER RESEARCH

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

(2008) Steffen Koschmieder et al.   JOURNAL OF CLINICAL ONCOLOGY